IHVV.ASX
Ishares S&P 500 Aud Hedged ETF
https://www.marketindex.com.au/asx/ihvv/financials
Annual Financial Summary
Print Financials
06/2023
06/2022
06/2021
06/2020
06/2019
06/2018
06/2017
06/2016
06/2015
N/A
Profitability
NPAT ($)
149,992,000
(82,819,000)
-
NPAT Margin
--
--
-
Abnormals ($)
-
-
-
NPAT before Abnormals ($)
149,992,000
(82,819,000)
-
Return on Equity (ROE)
13.05%
-14.75%
-
Return on Assets (ROA)
12.90%
-14.03%
-
Valuation
PE Ratio
7.59
(67.91)
-
PE Relative to Market
52.5%
0.0%
-
Price to Book
0.99
10.01
-
Price to Cash Flow
10.84
(97.01)
-
Shares Outstanding (M)
27.31
15.28
-
Market Cap ($M)
$1,138.07
$5,623.87
-
Enterprise Value ($M)
$1,137.62
$5,623.47
-
Performance
Total Shareholder Return
14.8%
-12.7%
-
Relative to Market
0.1%
-5.3%
-
Per Share
Earnings (EPS Adjusted)
549.32
-54.20
-
Earnings (with Abnormals)
549.32
-54.20
-
Cash Flow
(1,603.30)
3.00
-
Cash
0.02
0.03
-
Net Tangible Assets
42.10
36.75
-
Book Value
42.10
36.75
-
Share Price
$41.68
$368.03
-
Liquidity
Quick Ratio
0.04
1.19
-
Current Ratio
0.04
1.19
-
Efficiency
Asset Turnover
0.00
0.00
-
Inventory Turnover
-
-
-
Working Capital Turnover
0.00
0.00
-
Dividends
DPS (c)
57.67
553.12
-
Dividend yield
1.38%
1.50%
-
Franking
-
-
-
Gross DPS (c)
57.67
553.12
-
Gross Dividend Yield
1.38%
1.50%
-
Payout Ratio
10%
-
-
Member Content
Source:
Annual Financial Income Statement
Print Financials
06/2023
06/2022
06/2021
06/2020
06/2019
06/2018
06/2017
06/2016
06/2015
N/A
Revenue from Operations
Investment Income
12,392,000
7,035,000
-
Other Income
138,495,000
(89,225,000)
-
Expenses
(895,000)
(629,000)
-
Profit / Loss before income tax
149,992,000
(82,819,000)
-
Tax Expense
-
-
-
NPAT before Abnormals
149,992,000
(82,819,000)
-
Abnormals
-
-
-
Abnormals Tax
-
-
-
Net Abnormals
-
-
-
Outside Equity
-
-
-
Preference Dividends
-
-
-
Reported NPAT after Abnormals
149,992,000
(82,819,000)
-
EQUITY
Share End
27,305,000
152,810,000
-
Share Weighted
27,305,000
152,810,000
-
Ordinary Dividends
(8,450,000)
-
-
EPS Adjusted
5,493,200
(542,000)
-
EPS after Abs
5,493,206
(541,974)
-
Equity Profit / Loss
-
-
-
Member Content
Source:
Annual Financial Balance Sheet
Print Financials
06/2023
06/2022
06/2021
06/2020
06/2019
06/2018
06/2017
06/2016
06/2015
N/A
CURRENT ASSETS
Cash and Cash Equivalents
0.46
0.39
-
Receivables
0.07
33.78
-
Investments
-
-
-
Other Current Assets
-
-
-
Total Current Assets
0.52
34.17
-
NON-CURRENT ASSETS
Investments
1,162.43
556.19
-
Property
-
-
-
Other Non-Current Assets
-
-
-
Total Non-Current Assets
1,162.43
556.19
-
TOTAL ASSETS
1,162.95
590.36
-
CURRENT LIABILITIES
Creditors
11.84
0.1
-
Provisions
-
-
-
Other Liabilities
1.61
28.63
-
TOTAL CURRENT LIABILITIES
13.45
28.73
-
NON-CURRENT LIABILITIES
Borrowings
-
-
-
Deferred Tax
-
-
-
Other Non-Current Liabilities
-
-
-
TOTAL NON-CURRENT LIABILITIES
-
-
-
TOTAL LIABILITIES
13.45
28.73
-
NET ASSETS
1,176.4
619.09
-
Total Equity Attr. to Holders
1,149.51
561.63
-
Outside Equity
-
-
-
TOTAL EQUITY
1,149.51
561.63
-
Member Content
Source:
Annual Financial Cash Flow
Print Financials
06/2023
06/2022
06/2021
06/2020
06/2019
06/2018
06/2017
06/2016
06/2015
N/A
CASH FLOWS FROM OPERATING ACTIVITIES
Receipts
416.03
285.46
-
Payments
(866.49)
(288.1)
-
Funds from Operations
-
-
-
Dividends Received
12.46
7.07
-
Interest Received
0.01
-
-
Interest Paid
-
-
-
Tax Paid
-
-
-
Other Operating Cash
0.2
0.17
-
NET CASH FROM OPERATING ACTIVITIES
(437.79)
4.59
-
CASH FLOWS FROM INVESTING ACTIVITIES
Receipts
-
-
-
Payments
-
-
-
PP&E
-
-
-
Proceeds PP&E
-
-
-
Purchase Subsidiary
-
-
-
Proceeds Subsidiary
-
-
-
Loans Granted
-
-
-
Loans Repaid
-
-
-
Other Investing Cash
-
-
-
NET CASH FROM INVESTING ACTIVITIES
-
-
-
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from Issue
762.51
182.26
-
Proceeds from Borrowings
-
-
-
Borrowings
-
-
-
Dividends Paid
(7.84)
(110.09)
-
Other Financing Cash
(316.78)
(76.69)
-
NET CASH FROM FINANCING ACTIVITIES
437.89
(4.53)
-
NET CHANGE IN CASH
0.1
0.07
-
CASH AT START
0.39
0.38
-
Exchange Rate Adjustment
(0.03)
(0.05)
-
Other Cash Adjustment
-
-
-
CASH AT END
0.46
0.39
-
Member Content
Source: